JP2017507122A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507122A5 JP2017507122A5 JP2016549224A JP2016549224A JP2017507122A5 JP 2017507122 A5 JP2017507122 A5 JP 2017507122A5 JP 2016549224 A JP2016549224 A JP 2016549224A JP 2016549224 A JP2016549224 A JP 2016549224A JP 2017507122 A5 JP2017507122 A5 JP 2017507122A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- och
- heteroaryl
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 106
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 38
- 125000003118 aryl group Chemical group 0.000 claims 37
- 125000001072 heteroaryl group Chemical group 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 26
- 229910052799 carbon Inorganic materials 0.000 claims 26
- 125000003545 alkoxy group Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 22
- 239000011780 sodium chloride Substances 0.000 claims 22
- 125000004432 carbon atoms Chemical group C* 0.000 claims 17
- 229910052801 chlorine Inorganic materials 0.000 claims 16
- 229910052731 fluorine Inorganic materials 0.000 claims 16
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 16
- 125000002877 alkyl aryl group Chemical group 0.000 claims 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims 14
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 206010057668 Cognitive disease Diseases 0.000 claims 11
- 125000002757 morpholinyl group Chemical group 0.000 claims 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000001188 haloalkyl group Chemical group 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 9
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 8
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 6
- 229920000728 polyester Polymers 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 5
- 125000005418 aryl aryl group Chemical group 0.000 claims 5
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 5
- 206010001897 Alzheimer's disease Diseases 0.000 claims 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 4
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 4
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 4
- 239000010452 phosphate Substances 0.000 claims 4
- -1 piperazine-1- yl Chemical group 0.000 claims 4
- 210000002569 neurons Anatomy 0.000 claims 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-M 2,5-dihydroxybenzoate Chemical compound OC1=CC=C(O)C(C([O-])=O)=C1 WXTMDXOMEHJXQO-UHFFFAOYSA-M 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 claims 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 claims 2
- 229940022663 Acetate Drugs 0.000 claims 2
- 229940072107 Ascorbate Drugs 0.000 claims 2
- 229940001468 Citrate Drugs 0.000 claims 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 229940001447 Lactate Drugs 0.000 claims 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 238000010171 animal model Methods 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 239000011668 ascorbic acid Substances 0.000 claims 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 2
- 229940077388 benzenesulfonate Drugs 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 claims 2
- 230000001149 cognitive Effects 0.000 claims 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 2
- 229940050411 fumarate Drugs 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 229940114119 gentisate Drugs 0.000 claims 2
- 229940050410 gluconate Drugs 0.000 claims 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 2
- 229940014662 pantothenate Drugs 0.000 claims 2
- 235000019161 pantothenic acid Nutrition 0.000 claims 2
- 239000011713 pantothenic acid Substances 0.000 claims 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 2
- 229960001860 salicylate Drugs 0.000 claims 2
- 229940086735 succinate Drugs 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 2
- 230000031836 visual learning Effects 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 210000001320 Hippocampus Anatomy 0.000 claims 1
- 210000000225 Synapses Anatomy 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 230000003750 conditioning Effects 0.000 claims 1
- 230000001747 exhibiting Effects 0.000 claims 1
- 230000013016 learning Effects 0.000 claims 1
- 230000027928 long-term synaptic potentiation Effects 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 125000006542 morpholinylalkyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- WZFJLBOJKYGFEF-UHFFFAOYSA-N CC(C)(CCc(cc1)cc(Cl)c1Cl)N(C1)Cc2c1ccc(N1CCNCC1)c2 Chemical compound CC(C)(CCc(cc1)cc(Cl)c1Cl)N(C1)Cc2c1ccc(N1CCNCC1)c2 WZFJLBOJKYGFEF-UHFFFAOYSA-N 0.000 description 1
- PTUWOVNKEBSQFQ-UHFFFAOYSA-N CC(C)(CCc(cc1)cc(Cl)c1Cl)N(C1)Cc2c1cccc2N1CCNCC1 Chemical compound CC(C)(CCc(cc1)cc(Cl)c1Cl)N(C1)Cc2c1cccc2N1CCNCC1 PTUWOVNKEBSQFQ-UHFFFAOYSA-N 0.000 description 1
- AHZUPQMCJMEEEG-UHFFFAOYSA-N CC(C)(CCc(cc1)cc(Cl)c1O)N(C1)Cc2c1cccc2F Chemical compound CC(C)(CCc(cc1)cc(Cl)c1O)N(C1)Cc2c1cccc2F AHZUPQMCJMEEEG-UHFFFAOYSA-N 0.000 description 1
- PIZPESOCQKGFKQ-UHFFFAOYSA-N CC(C)(CCc(cc1)cc(Cl)c1OC)N(C1)Cc2c1cccc2C(N1CCNCC1)=O Chemical compound CC(C)(CCc(cc1)cc(Cl)c1OC)N(C1)Cc2c1cccc2C(N1CCNCC1)=O PIZPESOCQKGFKQ-UHFFFAOYSA-N 0.000 description 1
- JCAGXBJIOMJUGF-UHFFFAOYSA-N CC(C)(CCc(cc1)cc(OC)c1Cl)N(C1)Cc2c1cccc2F Chemical compound CC(C)(CCc(cc1)cc(OC)c1Cl)N(C1)Cc2c1cccc2F JCAGXBJIOMJUGF-UHFFFAOYSA-N 0.000 description 1
- XZCZFWPQKLICKI-UHFFFAOYSA-N CC(C)(CCc(cc1)cc(OC)c1O)N(C1)Cc2c1ccc(N1CCNCC1)c2 Chemical compound CC(C)(CCc(cc1)cc(OC)c1O)N(C1)Cc2c1ccc(N1CCNCC1)c2 XZCZFWPQKLICKI-UHFFFAOYSA-N 0.000 description 1
- CNLFWHNQKVQNGY-UHFFFAOYSA-N CC(C)(CCc(cc1)cc(OC)c1O)N(C1)Cc2c1cccc2N1CCNCC1 Chemical compound CC(C)(CCc(cc1)cc(OC)c1O)N(C1)Cc2c1cccc2N1CCNCC1 CNLFWHNQKVQNGY-UHFFFAOYSA-N 0.000 description 1
- NKBOGJLFBUBVAW-UHFFFAOYSA-N CC(C)(CCc(cc1)cc2c1[nH]nc2)N(C1)Cc2c1cccc2C(N1CCNCC1)=O Chemical compound CC(C)(CCc(cc1)cc2c1[nH]nc2)N(C1)Cc2c1cccc2C(N1CCNCC1)=O NKBOGJLFBUBVAW-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)(CCc1cc(*)c(C)cc1)N1Cc2c(*)c(*)c(*)c(*)c2C1 Chemical compound CC(C)(CCc1cc(*)c(C)cc1)N1Cc2c(*)c(*)c(*)c(*)c2C1 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461934528P | 2014-01-31 | 2014-01-31 | |
US61/934,528 | 2014-01-31 | ||
PCT/US2015/013754 WO2015116923A1 (en) | 2014-01-31 | 2015-01-30 | Isoindoline compositions and methods for treating neurodegenerative disease |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017507122A JP2017507122A (ja) | 2017-03-16 |
JP2017507122A5 true JP2017507122A5 (US07846941-20101207-C00217.png) | 2018-03-08 |
JP6517827B2 JP6517827B2 (ja) | 2019-05-22 |
Family
ID=53757753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016549224A Active JP6517827B2 (ja) | 2014-01-31 | 2015-01-30 | イソインドリン組成物および神経変性疾患の治療方法 |
Country Status (16)
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201608528YA (en) | 2011-12-21 | 2016-12-29 | Novira Therapeutics Inc | Hepatitis b antiviral agents |
CR20200276A (es) | 2012-08-28 | 2021-01-27 | Janssen Sciences Ireland Uc | Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059) |
JP6466348B2 (ja) | 2013-02-28 | 2019-02-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用 |
CA2922302C (en) | 2013-04-03 | 2021-08-03 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
CA2935719C (en) | 2013-07-25 | 2021-11-02 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
AP2016009122A0 (en) | 2013-10-23 | 2016-03-31 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
AU2015210852B2 (en) | 2014-01-31 | 2019-01-24 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
KR20160128305A (ko) | 2014-02-05 | 2016-11-07 | 노비라 테라퓨틱스, 인코포레이티드 | Hbv 감염의 치료를 위한 병용 요법 |
PL3102572T3 (pl) | 2014-02-06 | 2019-04-30 | Janssen Sciences Ireland Uc | Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B |
WO2016149581A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
AU2016330964B2 (en) | 2015-09-29 | 2021-04-01 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
US11046670B2 (en) | 2015-10-19 | 2021-06-29 | Board Of Regents, The University Of Texas System | Piperazinyl norbenzomorphan compounds and methods for using the same |
AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
AU2017257153A1 (en) | 2016-04-29 | 2018-11-22 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
CN107162944B (zh) * | 2017-04-27 | 2019-02-26 | 湖南化工研究院有限公司 | 2,3-二甲基苯甲硫醚的制备方法 |
CA3061787A1 (en) * | 2017-05-15 | 2018-11-22 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
US20200338045A1 (en) * | 2017-11-01 | 2020-10-29 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
EA202092171A1 (ru) | 2018-03-14 | 2020-12-01 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Схема дозирования модулятора сборки капсида |
CN112930174A (zh) * | 2018-10-31 | 2021-06-08 | 波利科尔疗法公司 | 用于合成d3多巴胺受体激动剂的方法 |
KR20210130753A (ko) | 2019-02-22 | 2021-11-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체 |
CN111848466A (zh) * | 2019-03-08 | 2020-10-30 | 新昌县大船畈生物科技有限公司 | 一种食用香精香料的制备方法 |
CN109734638A (zh) * | 2019-03-08 | 2019-05-10 | 新昌县大船畈生物科技有限公司 | 一种食用香精香料的制备方法 |
CN113795486A (zh) | 2019-05-06 | 2021-12-14 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
CN112694427B (zh) * | 2019-10-23 | 2022-11-18 | 江西天宇化工有限公司 | 一种制备2,3-二甲基苯甲硫醚的方法 |
US20230098944A1 (en) * | 2020-02-13 | 2023-03-30 | Cognition Therapeutics, Inc. | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
WO2021236879A1 (en) | 2020-05-20 | 2021-11-25 | The Board Of Trustees Of The University Of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
CA3200346A1 (en) * | 2020-12-11 | 2022-06-16 | Anthony Caggiano | Compositions for treating dry age-related macular degeneration (amd) |
WO2024020059A1 (en) * | 2022-07-18 | 2024-01-25 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA732136B (en) | 1972-04-12 | 1974-03-27 | Lilly Co Eli | Dopamine derivatives |
DE2753278A1 (de) | 1977-11-30 | 1979-05-31 | Basf Ag | Aralkylpiperidinone |
US4321386A (en) | 1981-01-28 | 1982-03-23 | Mead Johnson & Company | Quaternary piperidinium halides |
DE3222152A1 (de) | 1982-06-12 | 1983-12-15 | Bayer Ag, 5090 Leverkusen | Substituierte maleinsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
PH20912A (en) | 1983-01-31 | 1987-05-28 | Lilly Co Eli | -phenethanolamine derivatives useful for promoting the growth, improving the efficiency of feed utilization and improving the leanless of domesticated animals |
JPS62283922A (ja) | 1986-05-30 | 1987-12-09 | Tsumura Juntendo Inc | 血小板凝集抑制剤 |
US4697024A (en) | 1986-11-24 | 1987-09-29 | Merrell Dow Pharmaceuticals Inc. | Medroxalol intermediates |
US4958029A (en) * | 1987-01-13 | 1990-09-18 | Banyu Pharmaceutical Co., Ltd. | Process for the production of isoindoline derivatives, novel intermediates and process for their production |
JPH01180822A (ja) | 1988-01-12 | 1989-07-18 | Dainippon Pharmaceut Co Ltd | 抗遅延型アレルギー剤 |
JPH01305085A (ja) | 1988-05-31 | 1989-12-08 | Yamanouchi Pharmaceut Co Ltd | ピリジルチアゾリジンカルボン酸アミド誘導体 |
JPH02215789A (ja) | 1989-02-15 | 1990-08-28 | Yamanouchi Pharmaceut Co Ltd | チアゾロ[3,4―a]ピラジン誘導体 |
CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
DE4000610A1 (de) | 1990-01-11 | 1991-07-18 | Knoll Ag | Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen |
JP2818958B2 (ja) | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法 |
JPH045266A (ja) | 1990-04-24 | 1992-01-09 | Toyo Pharma- Kk | ドパミン誘導体の製造方法 |
DE4142366A1 (de) | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DK0724561T3 (da) | 1991-08-23 | 2004-06-28 | Nps Pharma Inc | Calciumreceptoraktive arylalkylaminer |
US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
JPH06321781A (ja) | 1993-05-13 | 1994-11-22 | Yamanouchi Pharmaceut Co Ltd | 血小板活性化因子拮抗剤 |
DK1203761T3 (da) | 1994-12-08 | 2005-04-11 | Nps Pharma Inc | Calciumreceptoraktive forbindelser |
JP3522930B2 (ja) | 1995-12-06 | 2004-04-26 | 花王株式会社 | 抗菌剤及びこれを含有する口腔用組成物 |
EP0881220A4 (en) | 1996-02-15 | 1999-04-21 | Mitsubishi Chem Corp | DIARYLSULTAME DERIVATIVES |
EP0915888A1 (en) * | 1996-04-24 | 1999-05-19 | Takeda Chemical Industries, Ltd. | Fused imidazopyridine derivatives as antihyperlipidemic agents |
US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US6518315B1 (en) | 1997-10-21 | 2003-02-11 | The University Of Sydney | Medicinal uses of phenylaikanols and derivatives |
CO4980891A1 (es) | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
CO5011072A1 (es) | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
IL138686A0 (en) | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
WO2001030335A2 (en) | 1999-10-22 | 2001-05-03 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
DE10027151A1 (de) | 2000-05-31 | 2001-12-06 | Bayer Ag | Herbizide Mittel auf Basis von substituierten Carbonsäureamiden |
IL153231A0 (en) | 2000-06-28 | 2003-07-06 | Smithkline Beecham Plc | Wet milling process |
IL157766A0 (en) | 2001-03-05 | 2004-03-28 | Yissum Res Dev Co | Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses |
JP4312402B2 (ja) | 2001-07-31 | 2009-08-12 | 有限会社大長企画 | 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤 |
US20030073681A1 (en) | 2001-08-21 | 2003-04-17 | Hauske James R. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
US6991814B2 (en) | 2001-12-13 | 2006-01-31 | Council Of Scientific And Industrial Research | Herbal medicaments for the treatment of neurocerebrovascular disorders |
AU2002348802A1 (en) | 2001-12-14 | 2003-06-30 | Council Of Scientific And Industrial Research | Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders |
JP2004002517A (ja) | 2002-05-31 | 2004-01-08 | Dae Sil Kim | 生姜成分を含む石鹸の組成物及びその製造方法 |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
DE10320560A1 (de) | 2003-05-07 | 2004-01-29 | Brosig, Stefan, Dr. | Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit |
US7829562B2 (en) | 2003-06-12 | 2010-11-09 | M's Science Corporation | Sigma ligands for neuronal regeneration and functional recovery |
WO2004110387A2 (en) | 2003-06-12 | 2004-12-23 | Agy Therapeutics, Inc. | Sigma ligands for neuronal regeneration and functional recovery |
WO2005087212A1 (en) | 2004-03-12 | 2005-09-22 | Egis Gyógyszergyár Nyrt. | Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |
RU2006147249A (ru) | 2004-05-31 | 2008-07-20 | Канека Корпорейшн (Jp) | Агент для предотвращения/облегчения заболеваний, связанных с образом жизни, содержащий компонент эфирного масла куркумы |
AU2005253776B8 (en) | 2004-06-21 | 2012-02-02 | King's College London | Screening methods using c-Abl, Fyn and Syk in combination with tau protein |
TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
AU2005281783A1 (en) | 2004-09-10 | 2006-03-16 | Ucb Pharma, S.A. | Sigma receptor ligands |
US20080044356A1 (en) | 2004-10-22 | 2008-02-21 | Regents Of The University Of Minnesota | Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof |
WO2006066118A2 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment |
EP1861422B1 (en) | 2005-03-05 | 2010-02-24 | Abbott GmbH & Co. KG | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
CA2611489A1 (en) | 2005-06-15 | 2006-12-28 | Darrick S.H.L. Kim | Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease including sage and rosemary derived compounds |
TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
EP1745778A3 (en) | 2005-07-20 | 2007-03-07 | Speedel Experimenta AG | Diaminoalcohols as therapeutic compounds |
ITRM20060007A1 (it) | 2006-01-05 | 2007-07-06 | Univ Bari | Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici |
US20070218491A1 (en) | 2006-02-08 | 2007-09-20 | Oligomerix, Inc. | Oligomerization of amyloid proteins |
US20080193573A1 (en) | 2006-03-17 | 2008-08-14 | Gow Robert T | Extracts and methods comprising curcuma species |
US20100029654A1 (en) | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
WO2007126473A2 (en) | 2006-04-10 | 2007-11-08 | Oligomerix, Inc. | Oligomerization of amyloid proteins |
EP2035448A4 (en) | 2006-06-01 | 2010-11-03 | Elan Pharm Inc | NEUROACTIVE FRAGMENTS OF APP |
US7561775B2 (en) | 2006-08-22 | 2009-07-14 | Senko Advanced Components, Inc. | Fiber optic protective shutter |
EP2066692B1 (en) | 2006-09-08 | 2012-01-11 | VIB, vzw | Means and methods for the production of amyloid oligomers |
US7723377B2 (en) | 2006-09-29 | 2010-05-25 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
US20080131233A1 (en) | 2006-10-17 | 2008-06-05 | Yao Chun I | Plate-shaped fastener device |
WO2008076262A2 (en) | 2006-12-15 | 2008-06-26 | Merck & Co., Inc. | Receptor for amyloid beta and uses thereof |
US20080171757A1 (en) | 2007-01-11 | 2008-07-17 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Serivces | Methods to identify inhibitors of cell sickling |
WO2008134034A1 (en) | 2007-04-26 | 2008-11-06 | Yale University | Prion protein as a receptor for amyloid-beta oligomers |
CN101808647A (zh) | 2007-05-15 | 2010-08-18 | 海利空医疗公司 | 通过抑制Gpr12治疗认知障碍的方法 |
CN101121670A (zh) | 2007-09-11 | 2008-02-13 | 上海紫源制药有限公司 | 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法 |
WO2009048631A1 (en) | 2007-10-11 | 2009-04-16 | University Of Tennessee Research Foundation | PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF |
WO2009054468A1 (ja) | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | アゾールカルボキサミド化合物又はその塩 |
WO2009059214A1 (en) | 2007-11-02 | 2009-05-07 | The Regents Of The University Of California | Abeta-binding small molecules |
WO2009067493A2 (en) | 2007-11-19 | 2009-05-28 | Envivo Pharmaceuticals, Inc. | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
US20110092445A1 (en) | 2008-07-25 | 2011-04-21 | Abbott Laboratories | Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses |
WO2010062260A1 (en) | 2008-11-29 | 2010-06-03 | The Thailand Research Fund | Virus and target cell interaction inhibition |
WO2010088450A2 (en) | 2009-01-30 | 2010-08-05 | Celladon Corporation | Methods for treating diseases associated with the modulation of serca |
DK3255146T3 (da) | 2009-03-16 | 2019-08-19 | Pangu Biopharma Ltd | Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter |
US7972164B2 (en) | 2009-03-24 | 2011-07-05 | Tyco Electronics Corporation | Connector assembly with a latch |
SG176772A1 (en) | 2009-04-09 | 2012-01-30 | Cognition Therapeutics Inc | Inhibitors of cognitive decline |
US9493834B2 (en) | 2009-07-29 | 2016-11-15 | Pharnext | Method for detecting a panel of biomarkers |
ES2547730T3 (es) * | 2009-07-31 | 2015-10-08 | Cognition Therapeutics, Inc. | Inhibidores del deterioro cognitivo |
US20150160228A1 (en) | 2010-02-05 | 2015-06-11 | Susan Catalano | Compositions and method for determining the efficacy of amyloidosis treatments |
US20130071330A1 (en) | 2010-02-26 | 2013-03-21 | Susan Catalano | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
WO2012027548A1 (en) | 2010-08-25 | 2012-03-01 | The Feinstein Institute For Medical Research | Compounds and methods for prevention and treatment of alzheimer's and other diseases |
US20170049723A1 (en) | 2011-02-02 | 2017-02-23 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
AU2012212219B2 (en) | 2011-02-02 | 2017-03-23 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
AU2012298614A1 (en) | 2011-08-25 | 2014-04-10 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
EP2747768A4 (en) | 2011-08-25 | 2015-10-21 | Cognition Therapeutics Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
AT511906B1 (de) | 2011-08-30 | 2016-05-15 | Blum Gmbh Julius | Schublade |
WO2015020523A1 (en) | 2013-08-07 | 2015-02-12 | Stichting Vu-Vumc | Biomarkers for early diagnosis of alzheimer's disease |
AU2015210852B2 (en) * | 2014-01-31 | 2019-01-24 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
CA3061787A1 (en) | 2017-05-15 | 2018-11-22 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
US20200338045A1 (en) * | 2017-11-01 | 2020-10-29 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
CN110283082A (zh) | 2019-07-15 | 2019-09-27 | 泰州职业技术学院 | 一种3-苯基丙胺的制备方法 |
US20230098944A1 (en) | 2020-02-13 | 2023-03-30 | Cognition Therapeutics, Inc. | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
CA3200346A1 (en) | 2020-12-11 | 2022-06-16 | Anthony Caggiano | Compositions for treating dry age-related macular degeneration (amd) |
-
2015
- 2015-01-30 AU AU2015210852A patent/AU2015210852B2/en active Active
- 2015-01-30 ES ES15743281T patent/ES2721001T3/es active Active
- 2015-01-30 EP EP19154222.4A patent/EP3498692B1/en active Active
- 2015-01-30 RU RU2016134677A patent/RU2692258C2/ru active
- 2015-01-30 JP JP2016549224A patent/JP6517827B2/ja active Active
- 2015-01-30 DK DK15743281.6T patent/DK3099296T3/en active
- 2015-01-30 EP EP15743281.6A patent/EP3099296B1/en active Active
- 2015-01-30 MX MX2016009845A patent/MX368755B/es active IP Right Grant
- 2015-01-30 BR BR112016017808-4A patent/BR112016017808B1/pt active IP Right Grant
- 2015-01-30 NZ NZ722599A patent/NZ722599A/en unknown
- 2015-01-30 DK DK19154222.4T patent/DK3498692T3/da active
- 2015-01-30 KR KR1020167023951A patent/KR102331422B1/ko active IP Right Grant
- 2015-01-30 EP EP22155541.0A patent/EP4023294A1/en active Pending
- 2015-01-30 ES ES19154222T patent/ES2915833T3/es active Active
- 2015-01-30 WO PCT/US2015/013754 patent/WO2015116923A1/en active Application Filing
- 2015-01-30 US US15/115,187 patent/US9796672B2/en active Active
- 2015-01-30 CA CA2938212A patent/CA2938212C/en active Active
- 2015-01-30 CN CN201580017497.0A patent/CN106163516B/zh active Active
-
2016
- 2016-07-28 IL IL247003A patent/IL247003B/en active IP Right Grant
- 2016-12-13 HK HK16114172A patent/HK1225651A1/zh unknown
-
2017
- 2017-09-11 US US15/700,923 patent/US10207991B2/en active Active
-
2018
- 2018-12-21 US US16/230,238 patent/US10611728B2/en active Active
-
2020
- 2020-02-06 US US16/783,943 patent/US11691947B2/en active Active
-
2023
- 2023-04-27 US US18/308,037 patent/US20240150288A1/en active Pending